Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics (CLDI) has shared an announcement.
The Company has announced a reverse stock split of its common stock at a 1-for-10 ratio, aimed at consolidating shares and possibly boosting the stock price. This strategic move, detailed in a recent press release, is significant information for investors though it’s specified not to have any legal implications for the company’s filings or liabilities under the Securities Exchange Act.
Learn more about CLDI stock on TipRanks’ Stock Analysis page.